Aurobindo Pharma surges on plan to acquire 25% stake in Silicon Life Sciences

13 Sep 2013 Evaluate

Aurobindo Pharma is currently trading at Rs. 186.50, up by 3.75 points or 2.05% from its previous closing of Rs. 182.75 on the BSE.

The scrip opened at Rs. 184.00 and has touched a high and low of Rs. 187.55 and Rs. 184.00 respectively. So far 90009 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.90 on 07-Jan-2013 and a 52 week low of Rs. 122.20 on 17-Sep-2012.

Last one week high and low of the scrip stood at Rs. 195.65 and Rs. 179.95 respectively. The current market cap of the company is Rs. 5412.16 crore.

The promoters holding in the company stood at 54.84%, while Institutions and Non-Institutions held 31.65% and 13.51% respectively.

Aurobindo Pharma has received an approval to acquire 25% equity stake in Silicon Life Sciences (Silicon), a company engaged in manufacture of non-sterile penems, from the existing shareholder - ABS Mercantiles. Post this acquisition, the equity holding of the company would increase to 100%, thereby making Silicon a wholly owned subsidiary of the company. This acquisition will benefit the company in consolidating its operations. The board of director at its meeting held on September 12, 2013 has approved for the same.

The board has also decided to acquire 100% of the equity stake in Hyacinths Pharma (Hyacinths), a company incorporated to manufacture APIs, from the existing shareholders. Hyacinths is having land admeasuring 52 acres and 80 cents and is located in Srikakulam District, Andhra Pradesh which is near to the existing unit of the company at Pydibhimavaram, Srikakulam District, Andhra Pradesh.

Hyacinths’ is yet to commence its project but has the necessary statutory approvals in place. The location of the land is strategically ideal and convenient for expansion plans of the company in future. Post this acquisition, Hyacinths will become a wholly owned subsidiary of the company.

Further, in order to strengthen and provide focused growth to the injectables business, the board also approved the transfer of Injectables Unit IV as a going concern to Curepro Parenterals, a wholly owned subsidiary of the company pursuant to a scheme of arrangement. The Scheme is subject to requisite consent, approval of the shareholders, the High Court of Judicature at Hyderabad, Andhra Pradesh, Stock Exchanges, SEBI, the permission or approval of any other statutory or regulatory authorities, which by law may be necessary for the implementation of the Scheme.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×